Please ensure Javascript is enabled for purposes of website accessibility

Why NovoCure Stock Sank Today

By Keith Speights - Feb 25, 2021 at 3:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced delays of several clinical studies, with one analyst also predicting slower growth ahead.

What happened

Shares of NovoCure (NVCR 7.08%) were sinking 12.5% lower as of 3 p.m. EST on Thursday. The decline came after the company delayed several clinical studies and Evercore ISI analyst Vijay Kumar wrote to clients that NovoCure's growth is set to taper off.

So what

Kumar's gloomy prediction came after NovoCure announced its fourth-quarter results before the market open on Thursday.

The company reported revenue of $144 million, up 45% year over year and higher than the average analyst estimate of $141.3 million. NovoCure generated earnings in Q4 of $4.9 million, or $0.05 per share. Although this was better than earnings of $4.3 million, or $0.04 per share, posted in the prior-year period, it fell short of the consensus Wall Street earnings estimate of $0.12 per share. 

"Delayed" repeated on a sign

Image source: Getty Images.

NovoCure also announced that it's delaying a phase 2 study of its Tumor Treating Fields technology -- which uses electric fields to disrupt tumor growth, targeting liver cancer -- until the second quarter of 2021. A phase 2 test targeting stomach cancer and an interim analysis of a late-stage study targeting pancreatic cancer were pushed back until 2022.

Kumar's view that NovoCure's growth will slow, however, wasn't related to these delays. He pointed out to clients that the stock's gains in recent months were driven in large part by a sales backlog with Medicare patients. Now that that backlog has been largely worked down, NovoCure likely won't be able to add enough new patients to keep its strong growth rate going.

Growth stocks like NovoCure rely on everything going right to justify their premium valuations. When there are bumps in the road, share prices will fall as they did with NovoCure today.

Now what

NovoCure could have several potential catalysts on the way. The company expects to report final data from its phase 2 study in advanced liver cancer in the second quarter of this year. An interim analysis of a late-stage study in recurrent ovarian cancer should be on the way in the third quarter of 2021, with another late-stage interim analysis in non-small cell lung cancer anticipated in Q4 2021.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NovoCure Stock Quote
NovoCure
NVCR
$75.60 (7.08%) $5.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.